Touchstone
Last syncOct 31, 2026, 6:54 PM ET

INSP

Inspire Medical Systems, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$68.10Close $1.9BMarket cap $40.05 – $143.9952-week range Nov 2, 2026Next report · after the close

Highlights

Cautions

  • Not in an uptrend 3 of 8 trend conditions
  • Far from its high 53% below its 52-week high
  • Results soon Nov 2, 2026, in 1 day

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 3, 2026
Off 12-month high 53%
1wk down 4.2% price change
1mo down 1.8% price change
12-month return down 7% market up 11% · its own down 20%
F-score 6 / 9 Mixed
Altman Z 10.87 Low risk
P/E 13.4× price / earnings
PEG 0.07 P/E / EPS growth
P/B 2.5× price / book
Earnings yield up 2.8% EBIT / enterprise value
Cheaper than 54% of the market · around average
Revenue growth up 14% year on year
EPS growth — latest quarter
Sales growth down 8% latest quarter · -9 pts
ROE up 20% return on equity
Free cash margin up 9% $78.5M FCF
D/E — long-term debt / equity
Net debt / EBITDA -1.6× net cash
Interest cover —EBIT / interest
Piotroski tests
  • profits not fully backed by cash
  • short-term liquidity weakened
  • assets working less efficiently
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • reduced long-term debt
  • no new shares issued
  • gross margin widened

Trade setup

ATR% 4.1% $2.77 a day · 2×ATR $62.57
RS 67 / 99 vs the universe
Trend 3 / 8 trend template
Relative volume 1.0× vs 50-day average
Up/down volume 1.13 50 sessions
Implied move — no option chain · report Nov 2, 2026
Trend template · 3 of 8
  • Price above the 150 and 200-day averages: passes
  • 150-day average above the 200-day: fails
  • 200-day average rising for a month: fails
  • 50-day average above the 150 and 200-day: passes
  • Price above the 50-day average: fails
  • At least 30% above the 52-week low: passes
  • Within 25% of the 52-week high: fails
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Aug 3, 2026
Results reaction Aug 3, 2026+24% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $912.0M +14% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $115.4M FY2021 · $233.4M FY2022 · $407.9M FY2023 · $624.8M FY2024 · $802.8M FY2025 · $912.0M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $145.4M +172% on FY2024
-$100M $0 $200M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$57.2M FY2021 · -$42.0M FY2022 · -$44.9M FY2023 · -$21.2M FY2024 · $53.5M FY2025 · $145.4M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $78.5M -14% on FY2024
-$100M $0 $100M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$55.5M FY2021 · -$24.8M FY2022 · $2.5M FY2023 · $1.0M FY2024 · $91.1M FY2025 · $78.5M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 85%
  • Net 16%
  • Free cash 9%
-50% 0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 85% · Net -50% · Free cash -48% FY2021 · Gross 86% · Net -18% · Free cash -11% FY2022 · Gross 84% · Net -11% · Free cash 1% FY2023 · Gross 85% · Net -3% · Free cash 0% FY2024 · Gross 85% · Net 7% · Free cash 11% FY2025 · Gross 85% · Net 16% · Free cash 9%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $500M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $190.5M · Long-term debt $24.5M FY2021 · Cash $214.5M · Long-term debt $24.5M FY2022 · Cash $441.6M · Long-term debt $0 FY2023 · Cash $185.5M FY2024 · Cash $150.2M FY2025 · Cash $104.8M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 28.58m +5.6% since FY2020
29.74m 27.07m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 27.07m FY2021 · 27.42m FY2022 · 29.01m FY2023 · 29.56m FY2024 · 29.74m FY2025 · 28.58m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $115.4M $233.4M $407.9M $624.8M $802.8M $912.0M
Gross margin 85% 86% 84% 85% 85% 85%
Operating income -$56.2M -$39.9M -$47.6M -$40.3M $36.1M $51.0M
Net income -$57.2M -$42.0M -$44.9M -$21.2M $53.5M $145.4M
Net margin -50% -18% -11% -3% 7% 16%
Earnings per share -$2.19 -$1.54 -$1.60 -$0.72 $1.75 $4.89
Free cash flow -$55.5M -$24.8M $2.5M $1.0M $91.1M $78.5M
Free cash margin -48% -11% 1% 0% 11% 9%
Cash $190.5M $214.5M $441.6M $185.5M $150.2M $104.8M
Long-term debt $24.5M $24.5M $0 — — —
Shareholders' equity $229.7M $229.0M $496.0M $572.5M $689.7M $781.2M
Shares outstanding 27.07m 27.42m 29.01m 29.56m 29.74m 28.58m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 3, 2026 Quarterly ↗ Jun 30, 2026 34d
May 4, 2026 Quarterly ↗ Mar 31, 2026 34d
Feb 13, 2026 Annual ↗ Dec 31, 2025 44d
Nov 3, 2025 Quarterly ↗ Sep 30, 2025 34d
Aug 4, 2025 Quarterly ↗ Jun 30, 2025 35d
May 5, 2025 Quarterly ↗ Mar 31, 2025 35d
Feb 10, 2025 Annual ↗ Dec 31, 2024 41d
Nov 4, 2024 Quarterly ↗ Sep 30, 2024 35d
Aug 6, 2024 Quarterly ↗ Jun 30, 2024 37d
May 7, 2024 Quarterly ↗ Mar 31, 2024 37d
Feb 9, 2024 Annual ↗ Dec 31, 2023 40d
Nov 7, 2023 Quarterly ↗ Sep 30, 2023 38d

Current reports

FiledDisclosed
Aug 3, 2026 Results · Regulation FD ↗
Jul 24, 2026 Director or officer change ↗
Jul 22, 2026 Director or officer change ↗
Jun 26, 2026 Regulation FD ↗
May 5, 2026 Director or officer change · Charter or bylaws · Shareholder vote ↗
May 4, 2026 Results · Regulation FD ↗
Feb 11, 2026 Results · Charter or bylaws · Regulation FD ↗
Jan 12, 2026 Results · Director or officer change · Regulation FD ↗
Nov 17, 2025 Other events ↗
Nov 3, 2025 Results · Regulation FD ↗
Oct 10, 2025 Regulation FD ↗
Aug 26, 2025 Director or officer change · Regulation FD ↗